Details

Autor(en) / Beteiligte

• Varenhorst, Christoph, MD
• James, Stefan, MD, PhD
• Erlinge, David, MD, PhD
• Braun, Oscar Ö., MD, PhD
• Brandt, John T., MD
• Winters, Kenneth J., MD
• Jakubowski, Joseph A., PhD
• Olofsson, Sylvia, MSci
• Wallentin, Lars, MD, PhD
• Siegbahn, Agneta, MD, PhD

Titel

Assessment of P2Y12 inhibition with the point-of-care device Verify Now P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

Ist Teil von

• The American heart journal, 2009, Vol.157 (3), p.562.e1-562.e9

Erscheinungsjahr

2009

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background Variability in response to thienopyridines has led to the development of point-of-care devices to assess adenosine diphosphate (ADP)-induced platelet aggregation. These tests need to be evaluated in comparison to reference measurements of P2Y12 function during different thienopyridine treatments. Methods After a run-in on 75 mg aspirin, 110 subjects were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD) or prasugrel 60 mg LD/10 mg MD. Antiplatelet effects were evaluated by Verify Now P2Y12 (VN-P2Y12) device (Accumetrics, San Diego, CA), vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay, and light transmission aggregometry (LTA). Prasugrel's and clopidogrel's active metabolite concentration were also determined. Results Dose- and time-dependent inhibition of P2Y12 was evident with VN-P2Y12. There was strong correlation with VN-P2Y12 and VASP or LTA for all treatments through a wide range of P2Y12 function. At high levels of P2Y12 inhibition, platelet function measured by VN-P2Y12 was maximally inhibited and could not reflect further changes seen with VASP or LTA methods. Correlation was also observed between exposure to clopidogrel's active metabolite and VN-P2Y12 during MD and LD, whereas it was observed only with prasugrel MD. Conclusion The VN-P2Y12 correlated strongly with inhibition of P2Y12 function, as measured with either VASP or LTA. VN-P2Y12 also correlated to exposure to the active metabolite of prasugrel and clopidogrel up to levels associated with assumed saturation of the P2Y12 receptor.